Moderna Capitalizes On Its Headstart In COVID-19 Vaccines

Leaked List Shows Premium Price Secured With EU

 
• By Andrew McConaghie
  
Moderna looks set to earn over $9bn from its COVID-19 vaccine next year.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip